Overview

Glufast On Insulin Glargine Trial in Type 2 DM

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine.
Phase:
Phase 4
Details
Lead Sponsor:
JW Pharmaceutical
Treatments:
Inositol
Mitiglinide
Voglibose